Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis
Fatty acid synthase (FASN) is a key enzyme in fat biosynthesis that is over-expressed in advanced breast cancer stages. Cisplatin (CDDP) is a platinum-based drug used in the treatment of certain types of this disease. Although it was shown that FASN inhibition induced apoptosis by enhancing the cytotoxicity of certain drugs in breast cancer, its role in regulating the chemosensitivity of different types of breast cancer cells to CDDP-induced apoptosis is not established yet. Therefore, two different breast cancer cell lines; triple negative breast cancer (TNBC; MDA-MB-231) and triple positive breast cancer (TPBC; BT-474) cells were used to examine such role. We show that TNBC cells had naturally less fat content than TPBC cells. Subsequently, the fat content increased in both cells when treated with Palmitate rather than Oleate, whereas both fatty acids produced apoptotic ultra-structural effects and attenuated FASN expression. However, Oleate increased FASN expression in TPBC cells. CDDP decreased FASN expression and increased apoptosis in TNBC cells. These effects were further enhanced by combining CDDP with fatty acids. We also illustrate that the inhibition of FASN by either siRNA or exogenous inhibitor decreased CDDP-induced apoptosis in TPBC cells suggesting its role as an apoptotic factor, while an opposite finding was observed in TNBC cells when siRNA and fatty acids were used, suggesting its role as a survival factor. To our knowledge, we are the first to demonstrate a dual role of FASN in CDDP-induced apoptosis in breast cancer cells and how it can modulate their chemosensitivity.
KeywordsBreast cancer Fatty acid synthase Palmitate Oleate Apoptosis
We thank Dr. Ikhlas Ahmed for her guidance and advices in this study. This research was supported by the department of Allied Health Sciences, College of Medicine and Health Sciences at Sultan Qaboos University.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 1.WHO Cancer. http://www.who.int/cancer/en/. Accessed 22 April 2015
- 4.Kumar S, Burney I, Al-Ajmi A, Al-Moundhri M (2011) Changing trends of breast cancer survival in Sultanate of Oman. J Oncol 10:7Google Scholar
- 14.Pizer E, Thupari J, Han W, Pinn M, Chrest F, Frehywot G, Townsend C, Kuhajda F (2000) Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60:213–218Google Scholar
- 19.Yu D, Hung M (1999) Breast cancer chemosensitivity. Breast cancer. Springer, New York, pp 481–517Google Scholar
- 24.Nieman K, Kenny H, Penicka C, Ladanyi A, BuellGutbrod R, Zillhardt M, Romero I, Carey M, Mills G, Hotamisligil G, Yamada S, Peter M, Gwin K, Lengyel E (2014) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17(11): 1498–1503Google Scholar
- 25.Menendez J, Mehmi I, Atlas E, Colomer R, Lupu R (2004) Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-κB. Int J Oncol 24(3):591–608Google Scholar
- 26.Menendez J, Vellon L, Colomer R, Lupu R (2005) Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer 115(1):19–35CrossRefPubMedGoogle Scholar
- 34.Menendez J, Lupu R, Colomer R (2005) Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Drug News Prospect 18(6):375–385Google Scholar